Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript

Core Insights - The FDA has approved KRESLADI RP-L201, a gene therapy developed by Rocket Pharmaceuticals for treating severe leukocyte adhesion deficiency type 1 (LAD-I) [1] Company Overview - Rocket Pharmaceuticals is focused on developing innovative gene therapies for rare diseases, with KRESLADI RP-L201 being a significant advancement in their product pipeline [1] Industry Context - The approval of KRESLADI RP-L201 highlights the growing trend and importance of gene therapies in treating rare genetic disorders, indicating a positive shift in regulatory support for such treatments [1]